Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Ralph Duda

Endocrinology, Diabetes & Metabolism Springfield, MO Medical Doctor

NPI 1356436406 CMS profile 151655

909 E Republic Rd Ste D200, Springfield, MO 65807

Open in the dashboard

General payments

$644,268

952 records reported · program years 2019–2025

Research payments

$44,029

Paid to them · 3 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$2,401,207 paid to institutions, not to them · program years 2022–2025

Through program year 2025, Ralph Duda of Springfield, MO is reported in the CMS Open Payments database as having received $644,268 across 952 general payments and $44,029 in research payments paid to them. Separately, studies naming them as principal investigator received $2,401,207 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 98th percentile of Endocrinology, Diabetes & Metabolism profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

8 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $77,300 131
2024 General $83,109 121
2023 General $93,909 141
2022 General $91,556 131
2022 Research $44,029 3
2021 General $42,352 63
2020 General $89,520 124
2019 General $166,521 241

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Ralph Duda
  • Endocrinology, Diabetes & Metabolism median
  • Middle half of Endocrinology, Diabetes & Metabolism
  • National median

In program year 2025, general payments to Ralph Duda were reported at $77,300. Among 5,868 Endocrinology, Diabetes & Metabolism profiles paid that year, the median was $507 and the middle half received between $135 and $1,838.

Show as a table
Year Ralph Duda Endocrinology, Diabetes & Metabolism median Middle half National median
2019 $166,521 $494 $123–$2,253 $163
2020 $89,520 $335 $85–$1,841 $114
2021 $42,352 $398 $88–$1,981 $132
2022 $91,556 $364 $88–$1,568 $149
2023 $93,909 $420 $113–$1,614 $160
2024 $83,109 $440 $121–$1,646 $164
2025 $77,300 $507 $135–$1,838 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Lilly USA, LLC $511,298 735 payments
  2. Novo Nordisk Inc $77,975 96 payments
  3. Amgen Inc. $50,393 70 payments
  4. Eli Lilly and Company $2,590 22 payments
  5. Boehringer Ingelheim Pharmaceuticals, Inc. $1,705 10 payments
  6. Janssen Biotech, Inc. $70 5 payments
  7. AbbVie, Inc. $56 4 payments
  8. Mallinckrodt Hospital Products Inc. $54 3 payments
  9. UCB, Inc. $50 3 payments
  10. ANI Pharmaceuticals, Inc. $25 1 payment
  11. Other $50 3 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $595,979 443 payments
  2. Travel and Lodging $36,175 258 payments
  3. Food and Beverage $8,019 248 payments
  4. Consulting Fee $4,000 1 payment
  5. Education $95 2 payments
Products named General payments · program years 2019–2025
  1. MOUNJARO $289,442 391 payments
  2. TRULICITY $213,174 300 payments
  3. Repatha $50,301 65 payments
  4. Ozempic $38,251 48 payments
  5. Tresiba $21,277 24 payments
  6. Xultophy 100/3.6 $7,200 8 payments
  7. RYBELSUS $5,225 5 payments
  8. Wegovy $116 3 payments
  9. JARDIANCE $107 7 payments
  10. ZEPBOUND $105 4 payments
  11. Other $789 56 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Eli Lilly and Company $44,029 3 payments

Records

955 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Endocrinology, Diabetes & Metabolism in Missouri

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record